Heidelberg Pharma AG · XETR:HPHA

Heidelberg Pharma — German Equity Forum / EKF 2020

26 slides from Heidelberg Pharma's conference presentation, November 2020

  1. Slide 1: ATACs: a Unique New Mode of Action to Fight Cancer

    ATACs: a Unique New Mode of Action to Fight Cancer German Equity Forum / EKF, November 2020 © Heidelberg Pharma AG

  2. Slide 2: Safe Harbor

    Safe Harbor Forward looking statements This communication contains certain forward-looking statements, product liability and limitations of insurance, limitations of supplies, relating to the Company’s business, which can be identified by the use of competition from other biopharmaceutical, chemical

  3. Slide 3: Corporate Overview

    Corporate Overview Technology & Validation Business Model Proprietary ATAC projects Partnered projects Outlook & Financials © Heidelberg Pharma AG 3

  4. Slide 4: Heidelberg Pharma at a Glance

    Heidelberg Pharma at a Glance Developing new options to address major challenges in cancer therapy Our Company Our Mission Our Approach Listed as Heidelberg Pharma AG New option in cancer therapy with Inhibition of RNA Polymerase II Frankfurt Stock Exchange: HPHA a unique mode of action Amanitin as

  5. Slide 5: Management Team with Strong Pharma and R&D Experience

    Management Team with Strong Pharma and R&D Experience Dr. Jan Schmidt-Brand Prof. Dr. Andreas Pahl CEO / CFO CSO @ Heidelberg Pharma since 2001 @ Heidelberg Pharma since 2012 30 years’ experience in commercial and financial leadership positions in pharma Professor of Pharmacology and Toxicology at t

  6. Slide 6: Technology & Validation

    Corporate Overview Technology & Validation Business Model Proprietary ATAC projects Partnered projects Financials & Outlook © Heidelberg Pharma AG 6

  7. Slide 7: Antibody Targeted Amanitin Conjugates (ATACs)

    Antibody Targeted Amanitin Conjugates (ATACs) Combining the Best of Two Therapeutic Modalities ATAC = ADC with Amanitin as toxic payload Comprehensive IP protection Highly specific antibody • Chemical synthesis of toxins, • Antibodies for different tumor targets • Optimal linker attachment sites, •

  8. Slide 8: ATACs Fill the Gap – the Missing MoA of Cancer Chemotherapeutics

    Amanitin – the only currently known inhibitor of RNA polymerase II ATACs Fill the Gap – the Missing MoA of Cancer Chemotherapeutics Amanitin – novel mode of action for cancer therapy Purines and pyrimidines 6-Mercaptopurine (Inhibit syntheses) Amanitin specifically binds and inhibits Ribonucleotides

  9. Slide 9: Business Model

    Corporate Overview Technology & Validation Business Model Proprietary ATAC projects Partnered projects Outlook & Financials © Heidelberg Pharma AG 9

  10. Slide 10: Strategic Cornerstones

    Strategic Cornerstones Build proprietary ATAC Licensed legacy assets ATAC pipeline collaborations (non-ATACs) HDP-101 – ATAC targeted against BCMA Licensing collaborations with Additional upside potential (multiple myeloma) pharma and biotech from clinical programs Up to USD 113 million TLX250-CDx –

  11. Slide 11: Growing Pipeline of Proprietary and Partnered Programs

    Growing Pipeline of Proprietary and Partnered Programs Product Target Indication Research Preclinic Clinic Partner Proprietary ATAC pipeline I II III HDP-101 BCMA Multiple myeloma (DLBCL/CLL) Proprietary HDP-102 CDXX NHL Proprietary HDP-103 PSMA Prostate cancer Proprietary XX-ATACs n/a Solid / Hemat

  12. Slide 12: ADCs: Selected Deals in 2020

    ADCs: Selected Deals in 2020 Merck & Co. AstraZeneca signs deal acquires VelosBio with Daiichi Sankyo for US$2.75 bn worth US$6 bn Phase I ADC VLS-101 Rights to a Phase I ADC DS-1062 Two ADCs and a bispecific antibody in preclinical Joint development and development commercialization Gilead Sciences

  13. Slide 13: Proprietary ATAC Projects

    Corporate Overview Technology & Validation Business Model Proprietary ATAC projects Partnered projects Financials & Outlook © Heidelberg Pharma AG 13

  14. Slide 14: Multiple Myeloma Major Unmet Medical Need

    Multiple Myeloma Major Unmet Medical Need • Second most prevalent hematopoietic malignancy* Myeloma cells are • 70,000 deaths due to MM annually; median age at diagnosis is located in the bone marrow and grow 65-70 years there • Malignancy characterized by the proliferation of single clone Healthy S

  15. Slide 15: ATACs Kill Dormant Tumor Cells

    ATACs Kill Dormant Tumor Cells Lead Candidate HDP-101 Ex-vivo Model Comparison of anti-BCMA-ATAC (HDP-101) with MMAF (Auristatin Conjugate as used by GSK) on MM Patient Cells Non-dividing (quiescent) cells isolated from multiple myeloma patients bone marrow biopsies Dividing tumor cells from lab cel

  16. Slide 16: 17p Deletion – Use of Biomarker for Accelerated Clinical Development

    17p Deletion – Use of Biomarker Could Provide Opportunity for Accelerated Clinical Development Case study: HDP-101 for multiple myeloma Overall survival of MM patients with and without 17p deletion • MM patients with 17p deleted tumors have a very high medical need for new treatment options Lower su

  17. Slide 17: HDP-101 has best-in-class potential for relapsed/refractory multiple myeloma

    HDP-101 has best-in-class potential for relapsed / refractory multiple myeloma Unique preclinical features of HDP-101 Potential clinical benefit Efficacious on dormant tumor cells Longer PFS and MRD negativity Efficacious in ultra-low BCMA tumor cells Deeper responses and higher ORR Novel MoA to whi

  18. Slide 18: Partnered Projects

    Corporate Overview Technology & Validation Business Model Proprietary ATAC projects Partnered projects Outlook & Financials © Heidelberg Pharma AG 18

  19. Slide 19: Partner Magenta Making Important Progress in ATAC Programs for Conditioning

    Partner Magenta Making Important Progress in ATAC Programs for Conditioning Conditioning: ATAC-mediated Stem cell depletion before stem cell conditioning transplants or gene therapies Current regimen: Harsh chemotherapy or irradiation Magenta‘s approach: ATAC-mediated conditioning Collaboration enab

  20. Slide 20: Legacy Assets Licensed to Partner Telix

    Legacy Assets Licensed to Partner Telix – Imaging Agent TLX250-CDx and Therapeutic Agent TLX250 TLX250-CDx – diagnostic agent TLX250 – therapeutic agent 89Zirconium labelled girentuximab 177Lu-DOTA labelled girentuximab Benign • Non-invasive detection and staging • Therapeutic radioimmunoconjugate f

  21. Slide 21: Legacy Asset Licensed to Partner RedHill – RHB-107

    Legacy Asset Licensed to Partner RedHill – RHB-107 (upamostat) Evaluation in New Indications RHB-107 – UpA/S1 serine protease inhibitor Potential first-in-class small molecule targeting targeting cancer, inflammatory lung diseases, and gastrointestinal diseases • So far: Positive Phase II trials in

  22. Slide 22: Outlook & Financials

    Corporate Overview Technology & Validation Business Model Proprietary ATAC projects Partnered ATAC projects Outlook & Financials © Heidelberg Pharma AG 22

  23. Slide 23: Operational Outlook

    Operational Outlook ATAC technology HDP-101 – next steps planned • Submission of IND (US) and CTA (Germany) • Site activation & First Patient In • Continue biomarker development • Presentation at important Conference American Society of Hematology (ASH) in December 2020 • Presentation of Phase I/II

  24. Slide 24: Financials and Shares

    Financials and Shares FYR 2019 9M 2020 Guidance Revised guidance in € m 03/2020 09/2020 Sales revenue and other income 8.0 8.3 8.0 to 10.0 9.0 to 10.0 Operating expenses 18.1 20.7 20.0 to 24.0 26.0 to 28.0 R&D costs 10.9 13.5 - - Operating result (EBIT) (10.1) (12.5) (11.0) to (15.0) (16.0) to (19.0

  25. Slide 25: Financing and Shares

    Financing and Shares Financing • €14.4 m gross proceeds from private placement with dievini and selected institutional investors in April 2020 • Cash as of 31 August 2020: € 9.2 m, Cash reach is secured until mid-2021 based on current budget planning including the financing commitment of € 15 millio

  26. Slide 26: Investment Summary

    Investment Summary Disruptive first-in-humans mode of action provides high efficacy and potential for unique clinical advantages, including treatment of dormant tumor cells Increased efficacy against 17p deleted and aggressive tumor cells based on biomarker Validated by high quality collaborations (

Heidelberg Pharma — German Equity Forum / EKF 2020 on 6ix